Selected research
Industry Research
Drugs for Asthma and COPD Industry Research Report 2026
Market perspective
The global Drugs for Asthma and COPD market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drugs for Asthma and COPD market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drugs for Asthma and COPD market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drugs for Asthma and COPD market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drugs for Asthma and COPD include GSK, Teva, Novartis, Merck, Mylan, Roche, AstraZeneca, Vertex and Sumitomo Dainippon, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drugs for Asthma and COPD market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Asthma and COPD.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Asthma and COPD Market by Company
GSK
Teva
Novartis
Merck
Mylan
Roche
AstraZeneca
Vertex
Sumitomo Dainippon
Chiesi
Boehringer Ingelheim
Beximco
Drugs for Asthma and COPD Segment by Type
Inhalable & Nasal Spray
Oral
Others
Drugs for Asthma and COPD Segment by Application
Asthma
COPD
Drugs for Asthma and COPD Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Asthma and COPD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Asthma and COPD and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Asthma and COPD.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs for Asthma and COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Inhalable & Nasal Spray
- Oral
- Others
Applications
- Asthma
- COPD
Companies covered
- GSK
- Teva
- Novartis
- Merck
- Mylan
- Roche
- AstraZeneca
- Vertex
- Sumitomo Dainippon
- Chiesi
- Boehringer Ingelheim
- Beximco
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs for Asthma and COPD by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Inhalable & Nasal Spray
- 2.2.3 Oral
- 2.2.4 Others
- 2.3 Drugs for Asthma and COPD by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Asthma
- 2.3.3 COPD
- 2.4 Assumptions and Limitations
3 Drugs for Asthma and COPD Breakdown Data by Type
- 3.1 Global Drugs for Asthma and COPD Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs for Asthma and COPD Forecasted Market Size by Type (2027-2032)
4 Drugs for Asthma and COPD Breakdown Data by Application
- 4.1 Global Drugs for Asthma and COPD Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs for Asthma and COPD Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs for Asthma and COPD Market Perspective (2021-2032)
- 5.2 Global Drugs for Asthma and COPD Growth Trends by Region
- 5.2.1 Global Drugs for Asthma and COPD Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs for Asthma and COPD Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs for Asthma and COPD Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs for Asthma and COPD Market Dynamics
- 5.3.1 Drugs for Asthma and COPD Industry Trends
- 5.3.2 Drugs for Asthma and COPD Market Drivers
- 5.3.3 Drugs for Asthma and COPD Market Challenges
- 5.3.4 Drugs for Asthma and COPD Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs for Asthma and COPD Players by Revenue
- 6.1.1 Global Top Drugs for Asthma and COPD Players by Revenue (2021-2026)
- 6.1.2 Global Drugs for Asthma and COPD Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs for Asthma and COPD Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs for Asthma and COPD Head Office and Area Served
- 6.4 Global Drugs for Asthma and COPD Players, Product Type & Application
- 6.5 Global Drugs for Asthma and COPD Manufacturers Established Date
- 6.6 Global Drugs for Asthma and COPD Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs for Asthma and COPD Market Size (2021-2032)
- 7.2 North America Drugs for Asthma and COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 7.4 North America Drugs for Asthma and COPD Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs for Asthma and COPD Market Size (2021-2032)
- 8.2 Europe Drugs for Asthma and COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 8.4 Europe Drugs for Asthma and COPD Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Asthma and COPD Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs for Asthma and COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs for Asthma and COPD Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs for Asthma and COPD Market Size (2021-2032)
- 10.2 South America Drugs for Asthma and COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 10.4 South America Drugs for Asthma and COPD Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Asthma and COPD Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs for Asthma and COPD Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs for Asthma and COPD Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 GSK
- 12.1.1 GSK Company Information
- 12.1.2 GSK Business Overview
- 12.1.3 GSK Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.1.4 GSK Drugs for Asthma and COPD Product Portfolio
- 12.1.5 GSK Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.2.4 Teva Drugs for Asthma and COPD Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.3.4 Novartis Drugs for Asthma and COPD Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Merck
- 12.4.1 Merck Company Information
- 12.4.2 Merck Business Overview
- 12.4.3 Merck Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.4.4 Merck Drugs for Asthma and COPD Product Portfolio
- 12.4.5 Merck Recent Developments
- 12.5 Mylan
- 12.5.1 Mylan Company Information
- 12.5.2 Mylan Business Overview
- 12.5.3 Mylan Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.5.4 Mylan Drugs for Asthma and COPD Product Portfolio
- 12.5.5 Mylan Recent Developments
- 12.6 Roche
- 12.6.1 Roche Company Information
- 12.6.2 Roche Business Overview
- 12.6.3 Roche Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.6.4 Roche Drugs for Asthma and COPD Product Portfolio
- 12.6.5 Roche Recent Developments
- 12.7 AstraZeneca
- 12.7.1 AstraZeneca Company Information
- 12.7.2 AstraZeneca Business Overview
- 12.7.3 AstraZeneca Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.7.4 AstraZeneca Drugs for Asthma and COPD Product Portfolio
- 12.7.5 AstraZeneca Recent Developments
- 12.8 Vertex
- 12.8.1 Vertex Company Information
- 12.8.2 Vertex Business Overview
- 12.8.3 Vertex Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.8.4 Vertex Drugs for Asthma and COPD Product Portfolio
- 12.8.5 Vertex Recent Developments
- 12.9 Sumitomo Dainippon
- 12.9.1 Sumitomo Dainippon Company Information
- 12.9.2 Sumitomo Dainippon Business Overview
- 12.9.3 Sumitomo Dainippon Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.9.4 Sumitomo Dainippon Drugs for Asthma and COPD Product Portfolio
- 12.9.5 Sumitomo Dainippon Recent Developments
- 12.10 Chiesi
- 12.10.1 Chiesi Company Information
- 12.10.2 Chiesi Business Overview
- 12.10.3 Chiesi Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.10.4 Chiesi Drugs for Asthma and COPD Product Portfolio
- 12.10.5 Chiesi Recent Developments
- 12.11 Boehringer Ingelheim
- 12.11.1 Boehringer Ingelheim Company Information
- 12.11.2 Boehringer Ingelheim Business Overview
- 12.11.3 Boehringer Ingelheim Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.11.4 Boehringer Ingelheim Drugs for Asthma and COPD Product Portfolio
- 12.11.5 Boehringer Ingelheim Recent Developments
- 12.12 Beximco
- 12.12.1 Beximco Company Information
- 12.12.2 Beximco Business Overview
- 12.12.3 Beximco Revenue in Drugs for Asthma and COPD Business (2021-2026)
- 12.12.4 Beximco Drugs for Asthma and COPD Product Portfolio
- 12.12.5 Beximco Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst